Balyasny Asset Management
TARS icon

Balyasny Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Balyasny Asset Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-138,019
Closed -$5.59M – 3457
2025
Q2 		$5.59M Buy
138,019
+78,345
+131% +$3.53M 0.01% 1234
2025
Q1 		$3.07M Buy
+59,674
New +$2.95M 0.01% 1489

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Balyasny Asset Management's TARS Position: Q3 2025 in Review

Balyasny Asset Management sold out of Tarsus Pharmaceuticals (TARS) in Q3 2025, closing a stake of 138,019 shares — an estimated $5.59M sold.

Balyasny Asset Management first reported a position in TARS in Q1 2025 and held it in 2 quarters. The position peaked at $5.59M in Q2 2025. 220 funds tracked by Wall St. Rank hold TARS as of Q3 2025.

  • Balyasny Asset Management reported no remaining Tarsus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 138,019 Tarsus Pharmaceuticals shares in Q3 2025, an estimated $5.59M.
  • Balyasny Asset Management first reported a position in Tarsus Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Balyasny Asset Management's Tarsus Pharmaceuticals position peaked at $5.59M in Q2 2025.
  • 220 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.